IMAGO PHARMACEUTICALS
Imago Pharmaceuticals is a virtual, privately held company developing JNK-directed novel therapies.
IMAGO PHARMACEUTICALS
Industry:
Biotechnology Pharmaceutical
Website Url:
http://www.imago-pharma.com
Status:
Active
Similar Organizations
Maxim Pharmaceuticals
Maxim Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative cancer therapeutics.
Current Employees Featured
Founder
Official Site Inspections
http://www.imago-pharma.com
- Host name: 104.21.64.1
- IP address: 104.21.64.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Imago Pharmaceuticals"
Merck to Acquire Imago BioSciences, Inc. - Merck.com
Nov 21, 2022 Acquisition expands Merck’s growing hematology portfolio Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the …See details»
Merck to Acquire Imago BioSciences, Inc. - Merck.com
Merck, known as MSD outside of the United States and Canada, and Imago BioSciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, …See details»
Merck bulks up in haematology, buying Imago for …
4 days ago While its fabled takeover of Seagen is yet to materialise, Merck & Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago ...See details»
Merck & Co. to acquire Imago BioSciences | C&EN …
Nov 28, 2022 It’s not Seagen but another company that Merck & Co. will acquire this year. The pharma giant will pay a total of $1.35 billion for Imago BioSciences. Merck’s acquisition of Imago strengthens the larger firm’s presence in …See details»
Merck agrees to acquire Imago for $1.35bn
Nov 22, 2022 Merck (MSD outside North America) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences, …See details»
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
Dec 12, 2022 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding …See details»
Merck Announces $1.35 Billion Acquisition of Imago BioSciences
Nov 28, 2022 Merck, known as MSD outside of the United States and Canada, announced its intention to acquire Imago BioSciences, a clinical-stage biopharmaceutical company focused …See details»
Merck & Co. to acquire Imago BioSciences
Nov 23, 2022 It’s not Seagen but another company that Merck & Co. will acquire this year. The pharma giant will pay a total of $1.35 billion for Imago BioSciences.See details»
Imago BioSciences, Inc. - EverybodyWiki Bios & Wiki
Imago BioSciences, Inc. is a drug discovery and clinical development company focused on the treatment of bone marrow disorders. The key product candidate is bomedemstat currently …See details»
Organization | Imago BioSciences
Imago BioSciences Report issue For profit Phase 1 Phase 2 Founded: San Carlos CA United States (2012) Status: Acquired by Merck (2022) Organization Overview First Clinical Trial …See details»
Merck to acquire Imago for $1.35 billion to develop …
Nov 22, 2022 Merck has announced it will acquire biopharma Imago BioSciences, Inc for around $1.35 billion in total equity value, to facilitate development of Imago’s lead candidate bomedemstat (IMG-7289), an …See details»
Imago BioSciences Company Profile - Office Locations ... - Craft
Imago BioSciences is a clinical-stage biotechnology company developing treatments for myeloid diseases. It conducts research in bone marrow disease prevention and treatment, including …See details»
Merck’s $1.3B Imago Buyout Brings Blood Cancer Drug to Rival …
Nov 21, 2022 Merck is acquiring Imago BioSciences, a clinical-stage biotech whose lead drug is in development for myelofibrosis and other blood cancers. The deal gives the pharmaceutical …See details»
Imago BioSciences 2025 Company Profile: Valuation, Investors ...
Information on acquisition, funding, cap tables, investors, and executives for Imago BioSciences. Use the PitchBook Platform to explore the full profile.See details»
Imago Pharmaceuticals Company Profile | Management and
Imago Pharmaceuticals Profile and History Imago Pharmaceuticals, Inc. is a pharmaceutical company developing novel therapies for neurodegenerative, inflammatory and autoimmune …See details»
Merck to buy Imago for $1.35 bln to broaden portfolio of blood …
Nov 21, 2022 Merck & Co Inc said on Monday it will acquire cancer drug developer Imago BioSciences Inc for a total equity value of $1.35 billion to expand its portfolio of blood disorder …See details»
Imago BioSciences, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Imago BioSciences, Inc. with its drug pipeline, therapeutic area, technology platform, 11 clinical trials, 43 news, and 9 literature, Disease Domain:Hemic and ...See details»
Imago Pharmaceuticals - Crunchbase Company Profile & Funding
Imago Pharmaceuticals is a virtual, privately held company developing JNK-directed novel therapies.See details»
Imago BioSciences: The Bone Marrow Cancer Researcher Reaches …
Imago BioSciences, Inc. (IMGO), a U.S. biotech developer of innovative treatments for bone marrow cancer patients, will become part of the Merck & Co., Inc. (MRK) family under a …See details»
Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck
Nov 22, 2022 Imago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023.See details»